The loss of Karyopharm Therapeutics under GAAP for the 3 months of 2022 was $41.399 million, down 27.9% from $57.414 million in the previous year. Revenue increased 2.1 times to $47.67 million from $23.26 million a year earlier.
The loss of Karyopharm Therapeutics under GAAP for the 3 months of 2022 was $41.399 million, down 27.9% from $57.414 million in the previous year. Revenue increased 2.1 times to $47.67 million from $23.26 million a year earlier. 
investors.karyopharm.com
English (US) 